Avalo Therapeutics Completes Enrollment in Phase 2 LOTUS Trial for Hidradenitis Suppurativa Treatment
Key Insights
Avalo Therapeutics has completed enrollment of approximately 250 adults in its Phase 2 LOTUS trial evaluating AVTX-009 for moderate to severe hidradenitis suppurativa (search).
The global trial compares subcutaneous bi-weekly and monthly dosing regimens of AVTX-009 against placebo, with topline data expected in mid-2026.
Analysts project potential stock upside of over 200% if the drug achieves HiSCR75 response rates of 25-30%, with the company highlighting superior IL-1β (search) inhibition as a competitive advantage.
Avalo Therapeutics Inc. has completed enrollment in its Phase 2 LOTUS trial of AVTX-009, the company's lead drug candidate for treating hidradenitis suppurativa (search). The global trial includes approximately 250 adults with moderate to severe hidradenitis suppurativa to evaluate the efficacy and safety of subcutaneous bi-weekly and monthly dosing regimens compared to placebo, with topline data expected in mid-2026.
Trial Design and Primary Endpoint
The Phase 2 LOTUS trial focuses on the HiSCR75 endpoint, which is defined as greater than or equal to 75% reduction in the total abscess and inflammatory nodule count from baseline, with no increase in the number of abscesses or draining tunnels. This endpoint represents a stringent measure of clinical response in hidradenitis suppurativa (search) patients.
Analyst Projections and Market Potential
Cantor analyst Prakhar Agarwal outlined varying scenarios for AVTX-009's potential market performance based on HiSCR75 response rates. According to the analysis, if the drug achieves HiSCR75 changes of 18-19%, the stock could see upside, though this may be capped due to investor concerns about potential efficacy degradation from Phase 2 to Phase 3 trials.
More significant gains are projected for higher response rates: HiSCR75 changes of 20-25% could drive stock rallies of 100-150%, while response rates in the 25-30% range could result in stock increases exceeding 200%. Conversely, if the trial fails, analysts project the stock could decline 85-90%.
Competitive Positioning and Mechanism
Avalo's management has highlighted AVTX-009's "superior affinity" as its primary competitive advantage, which should lead to stronger IL-1β (search) inhibition for extended periods. This positioning comes amid competitive concerns, including Novartis AG's MAS825, an IL-1β/IL-18 (search) bispecific for hidradenitis suppurativa (search), though Cantor suggests that MAS825's modest efficacy may be due to lower potency or underdosing.
The company's management expressed confidence that AVTX-009 will demonstrate comparable or superior efficacy to AbbVie Inc.'s lutikizumab, another IL-1β (search) inhibitor in development for hidradenitis suppurativa (search).
Market Context and Precedent
Cantor referenced MoonLake Immunotherapeutics, which reached a market capitalization of $2-2.5 billion following Phase 2 data in hidradenitis suppurativa (search), despite initial skepticism about the market size for this indication. This precedent suggests significant market potential for successful hidradenitis suppurativa treatments.
Analyst Coverage and Stock Performance
AVTX has attracted positive analyst attention, with multiple firms initiating bullish coverage. Guggenheim set the highest target price at $50.00 in February, while HC Wainwright & Co. maintains a $25.00 target, Mizuho established a $39.00 target, and BTIG set a $40.00 target. Cantor maintains an Overweight rating for the stock.
Despite the positive analyst sentiment, Avalo Therapeutics' stock has underperformed, falling approximately 13% year-to-date compared to a 2% gain for the State Street SPDR S&P Biotech ETF. The stock was trading at $15.80, up 4.57% at the time of the analyst report.